HomeCompareBIOC vs GIS

BIOC vs GIS: Dividend Comparison 2026

BIOC yields 459.88% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOC wins by $32353.11M in total portfolio value
10 years
BIOC
BIOC
● Live price
459.88%
Share price
$0.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32353.19M
Annual income
$22,660,147,667.77
Full BIOC calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — BIOC vs GIS

📍 BIOC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOCGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOC + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOC pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOC
Annual income on $10K today (after 15% tax)
$39,089.45/yr
After 10yr DRIP, annual income (after tax)
$19,261,125,517.60/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, BIOC beats the other by $19,261,111,652.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOC + GIS for your $10,000?

BIOC: 50%GIS: 50%
100% GIS50/50100% BIOC
Portfolio after 10yr
$16176.63M
Annual income
$11,330,081,989.60/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

BIOC
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.7
Piotroski
3/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOC buys
0
GIS buys
0
No recent congressional trades found for BIOC or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOCGIS
Forward yield459.88%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$32353.19M$79.2K
Annual income after 10y$22,660,147,667.77$16,311.42
Total dividends collected$31493.31M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: BIOC vs GIS ($10,000, DRIP)

YearBIOC PortfolioBIOC Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$56,688$45,987.58$11,504$804.11+$45.2KBIOC
2$304,294$243,637.85$13,371$1,061.65+$290.9KBIOC
3$1,547,860$1,222,266.18$15,723$1,416.15+$1.53MBIOC
4$7,466,811$5,810,600.46$18,735$1,911.16+$7.45MBIOC
5$34,185,829$26,196,340.96$22,660$2,613.51+$34.16MBIOC
6$148,669,080$112,090,243.27$27,874$3,627.81+$148.64MBIOC
7$614,649,543$455,573,627.83$34,947$5,121.52+$614.61MBIOC
8$2,417,954,821$1,760,279,809.21$44,762$7,369.21+$2417.91MBIOC
9$9,058,914,211$6,471,702,552.56$58,728$10,832.80+$9058.86MBIOC
10$32,353,185,873$22,660,147,667.77$79,151$16,311.42+$32353.11MBIOC

BIOC vs GIS: Complete Analysis 2026

BIOCStock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Full BIOC Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this BIOC vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOC vs SCHDBIOC vs JEPIBIOC vs OBIOC vs KOBIOC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.